| pubmed-article:19189357 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19189357 | lifeskim:mentions | umls-concept:C0002395 | lld:lifeskim |
| pubmed-article:19189357 | lifeskim:mentions | umls-concept:C2700455 | lld:lifeskim |
| pubmed-article:19189357 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:19189357 | lifeskim:mentions | umls-concept:C0332621 | lld:lifeskim |
| pubmed-article:19189357 | lifeskim:mentions | umls-concept:C1947974 | lld:lifeskim |
| pubmed-article:19189357 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:19189357 | lifeskim:mentions | umls-concept:C1720655 | lld:lifeskim |
| pubmed-article:19189357 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:19189357 | pubmed:dateCreated | 2009-2-24 | lld:pubmed |
| pubmed-article:19189357 | pubmed:abstractText | A variety of human diseases are suspected to be directly linked to protein misfolding. Highly organized protein aggregates, called amyloid fibrils, and aggregation intermediates are observed; these are considered to be mediators of cellular toxicity and thus attract a great deal of attention from investigators. Neurodegenerative pathologies such as Alzheimer's disease account for a major part of these protein misfolding diseases. The last decade has witnessed a renaissance of interest in inhibitors of tau aggregation as potential disease-modifying drugs for Alzheimer's disease and other "tauopathies". The recent report of a phase II clinical trial with the tau aggregation inhibitor MTC could hold promise for the validation of the concept. This Review summarizes the available data concerning small-molecule inhibitors of tau aggregation from a medicinal chemistry point of view. | lld:pubmed |
| pubmed-article:19189357 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19189357 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19189357 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19189357 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19189357 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19189357 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19189357 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19189357 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19189357 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19189357 | pubmed:issn | 1521-3773 | lld:pubmed |
| pubmed-article:19189357 | pubmed:author | pubmed-author:WaldmannHerbe... | lld:pubmed |
| pubmed-article:19189357 | pubmed:author | pubmed-author:MandelkowEva-... | lld:pubmed |
| pubmed-article:19189357 | pubmed:author | pubmed-author:SchmidtBorisB | lld:pubmed |
| pubmed-article:19189357 | pubmed:author | pubmed-author:MandelkowEckh... | lld:pubmed |
| pubmed-article:19189357 | pubmed:author | pubmed-author:PickhardtMarc... | lld:pubmed |
| pubmed-article:19189357 | pubmed:author | pubmed-author:BulicBrunoB | lld:pubmed |
| pubmed-article:19189357 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19189357 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:19189357 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19189357 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19189357 | pubmed:pagination | 1740-52 | lld:pubmed |
| pubmed-article:19189357 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:meshHeading | pubmed-meshheading:19189357... | lld:pubmed |
| pubmed-article:19189357 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19189357 | pubmed:articleTitle | Development of tau aggregation inhibitors for Alzheimer's disease. | lld:pubmed |
| pubmed-article:19189357 | pubmed:affiliation | Max-Planck-Institute for Molecular Physiology, Dortmund, Germany. bruno.bulic@mpi-dortmund.mpg.de | lld:pubmed |
| pubmed-article:19189357 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19189357 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:19189357 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19189357 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19189357 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19189357 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19189357 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19189357 | lld:pubmed |
